Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor

Some patients treated with dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) can still exhibit heightened residual platelet reactivity (HRPR), which is potentially linked to adverse vascular outcomes. Better tailored DAPT strategies are needed to address this medical need. Aim...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nikita Lomakin, Anna Rudakova, Liudmila Buryachkovskaya, Victor Serebruany
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2019
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/a91ec16800854a1d82afd0cd6c911f1e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a91ec16800854a1d82afd0cd6c911f1e
record_format	dspace
spelling	oai:doaj.org-article:a91ec16800854a1d82afd0cd6c911f1e2021-12-04T16:02:14ZCost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor10.15420/ecr.2018.29.21758-37641758-3756https://doaj.org/article/a91ec16800854a1d82afd0cd6c911f1e2019-12-01T00:00:00Zhttps://www.ecrjournal.com/articles/Platelet-Function-Guided-Strategy-Clopidogrel-Ticagrelorhttps://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Some patients treated with dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) can still exhibit heightened residual platelet reactivity (HRPR), which is potentially linked to adverse vascular outcomes. Better tailored DAPT strategies are needed to address this medical need. Aim: To assess the cost-effectiveness of guided DAPT with clopidogrel or ticagrelor in addition to aspirin when using VerifyNow P2Y12 testing in post-ACS patients. Methods: The costs were calculated per 1,000 patients aged >55 years. It was assumed that all patients received either generic clopidogrel or ticagrelor for 1 year, and underwent VerifyNow P2Y12 assay testing before DAPT maintenance. Results: Guided DAPT will prevent five more MIs and six more deaths per 1,000 patients than a standard prescription of generic clopidogrel. The total predictive value of costs per patient is 32% lower if a guided strategy is used than if ticagrelor is given to all patients. Conclusion: Assessment of heightened residual platelet reactivity with P2Y12 assay in triaging DAPT post-ACS patients for 1 year is a cost-effective strategy that would reduce financial burden compared to routine administration of more expensive antiplatelet agents.Nikita LomakinAnna RudakovaLiudmila BuryachkovskayaVictor SerebruanyRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 14, Iss 3, Pp 175-178 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Nikita Lomakin Anna Rudakova Liudmila Buryachkovskaya Victor Serebruany Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
description	Some patients treated with dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) can still exhibit heightened residual platelet reactivity (HRPR), which is potentially linked to adverse vascular outcomes. Better tailored DAPT strategies are needed to address this medical need. Aim: To assess the cost-effectiveness of guided DAPT with clopidogrel or ticagrelor in addition to aspirin when using VerifyNow P2Y12 testing in post-ACS patients. Methods: The costs were calculated per 1,000 patients aged >55 years. It was assumed that all patients received either generic clopidogrel or ticagrelor for 1 year, and underwent VerifyNow P2Y12 assay testing before DAPT maintenance. Results: Guided DAPT will prevent five more MIs and six more deaths per 1,000 patients than a standard prescription of generic clopidogrel. The total predictive value of costs per patient is 32% lower if a guided strategy is used than if ticagrelor is given to all patients. Conclusion: Assessment of heightened residual platelet reactivity with P2Y12 assay in triaging DAPT post-ACS patients for 1 year is a cost-effective strategy that would reduce financial burden compared to routine administration of more expensive antiplatelet agents.
format	article
author	Nikita Lomakin Anna Rudakova Liudmila Buryachkovskaya Victor Serebruany
author_facet	Nikita Lomakin Anna Rudakova Liudmila Buryachkovskaya Victor Serebruany
author_sort	Nikita Lomakin
title	Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
title_short	Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
title_full	Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
title_fullStr	Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
title_full_unstemmed	Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
title_sort	cost-effectiveness of platelet function-guided strategy with clopidogrel or ticagrelor
publisher	Radcliffe Medical Media
publishDate	2019
url	https://doaj.org/article/a91ec16800854a1d82afd0cd6c911f1e
work_keys_str_mv	AT nikitalomakin costeffectivenessofplateletfunctionguidedstrategywithclopidogrelorticagrelor AT annarudakova costeffectivenessofplateletfunctionguidedstrategywithclopidogrelorticagrelor AT liudmilaburyachkovskaya costeffectivenessofplateletfunctionguidedstrategywithclopidogrelorticagrelor AT victorserebruany costeffectivenessofplateletfunctionguidedstrategywithclopidogrelorticagrelor
_version_	1718372753760845824

Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor

Ejemplares similares